Vitruvias Therapeutics recalls specific lot of 30 mg thyroid tablets due to superpotency risk

Patients taking this specific thyroid medication face a risk of hyperthyroidism, which can cause serious health symptoms, and should verify their prescription lot number immediately.

• •Vitruvias Therapeutics is recalling Lot 504950 of Thyroid Tablets, USP 30 mg.
• •The recall was initiated due to the potential for the tablets to be 'superpotent,' meaning they contain a higher concentration of the active ingredient than intended.
• •Superpotency can lead to hyperthyroidism, with symptoms including weight loss, muscle weakness, and chest pain.
• •Elderly individuals, infants, and pregnant women are at a higher risk for complications from hyperthyroidism.
• •The affected products were distributed between January 31, 2025, and September 30, 2025.
• •The recalled lot has an expiration date of September 30, 2026.
• •No adverse effects have been reported to the company as of the announcement date.
• •Patients are advised not to stop taking the medication without consulting a healthcare provider.
• •Wholesalers have been instructed to stop distributing the affected lot and arrange for its destruction.
• •Adverse reactions can be reported to the FDA’s MedWatch program.